
Opinion|Videos|July 18, 2024
NCCN Guidelines Revisions and ASCO 2024 Research Outlook
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series

- How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
- What data, results, or insights are you looking forward to coming out of ASCO 2024?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure
2
Top 5 Myasthenia Gravis Content of 2025
3
Impact of Medicaid Institution for Mental Diseases Exclusion on Serious Mental Illness Outcomes
4
House Republicans Block Vote on ACA Subsidy Extension
5









































